Antibacterials - Growth in resistance rates drives niche indications

The global antibacterial market, valued at $25.5 billion in 2005, is highly mature. Modest growth (CAGR 2001-2005: 5.1%) is fuelled by ageing, immunosuppression and emerging resistances, especially in the hospital and former niche markets (e.g. MRSA). The community market, however, is facing a value loss following the patent expiries of several blockbusters (e.g. Pfizer's Zithromax) in 2005.

In 2005 the global antibacterial market was valued at approximately $25.5 billion with a modest CAGR of 5.1% since 2001. The fastest growing classes were the carbapenems, glycopeptides and others (e.g. Pfizer's Zyvox (linezolid)). The best selling drug was J&J's/Sanofi-Aventis' Levaquin (levofloxacin) with global sales of $2.4 billion.

Although gram-positive infections such as MRSA have been a key focus over recent years, Datamonitor's opinion leader research revealed new concerns about gram-negative organisms such as acinetobacter, pseudomonas and ESBL producing strains.

Ageing, immunosuppression and resistances contribute to the rising incidence of severe infections and fuel the growth of the hospital market. In contrast, the community market is facing a value loss resulting from the patent expiries of blockbusters such as Zithromax (azithromycin) and the incursion of cheap generics.

Read more...

• Nosocomial Infections (21/05/2008)
• The Hospital antibacterials market (20/05/2008)

• Pricing and Reimbursement in Oncology (27/05/2008)
• Obesity (27/05/2008)
• Therapeutic Cancer Vaccines (27/05/2008)

• Alzheimer's Disease (26/05/2008)
• Biosimilars: Benchmarking the key players (26/05/2008)
• Atherosclerosis (26/05/2008)
• Melanoma (26/05/2008)
• Respiratory Syncytial Virus (RSV) (26/05/2008)
• Multiple Sclerosis (26/05/2008)
• Osteoarthritis (26/05/2008)
• Psoriasis (26/05/2008)
• eHealth for the Pharmaceutical Industry (26/05/2008)

---